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Editorial
Looking back on the history of medical care, noteworthy diseases 
have changed along with long history. For recent years, metabolic 
syndrome (Met-S) has been increasing all over the world, which is an 
important health, medical and social problems [1,2]. Its prevalence 
has been higher in developed countries so far [3]. Nowadays, 
however, there has also been an increase in developing countries and 
appropriate action has been strongly needed.
Basically, the pathophysiology of Met-S has been insulin resistance 
and impaired regulation of lipid metabolism is also associated [4-6]. 
Among them, the genetic predisposition is a factor of Met-S, and the 
prevalence of Met-S differs depending on the ethnic group [7]. For 
example, the HDL gene has strong relevance and may be inherited 
by 70% [8]. Furthermore, several factors have affected by lifestyle 
habitual factors, age, socioeconomic status, and so on [9].
Regarding the frequency of Met-S, results somewhat differ 
depending on diagnostic criteria. However, the prevalence of Met-S 
has been increasing more and more in both developed and developing 
countries [9]. As a standard or average estimation, the prevalence 
in adults seems to be about 20-25% worldwide [10]. As Met-S has 
increased rapidly, the prevalence of type 2 diabetes, hypertension, 
cardiovascular disease, obesity have also increased in parallel [11]. 
Metabolic syndrome includes obesity as a fundamental 
pathophysiological status, and also hypertension, diabetes, dyslipidemia, 
and so on. Among them, in this article I would like to introduce several 
recent findings on hypertension and diabetes. 
As to hypertension, its frequency is high around the world. Various 
guidelines have been announced in each area or country. Regarding 
hypertension and heart disease, guidelines have been announced in 
Europe [12,13], North America and in Japan [14-16]. Furthermore, 
there are guidelines on young generation and the elderly, lipid and 
obesity, which also covers widely relating to hypertension and heart 
disease [17-20].Therefore, treatment of hypertension will be necessary 
to comprehensively utilize each guideline for management.
When hypertensive patients are treated, antihypertensive drugs 
are not given from the beginning. It is important to start correcting or 
adjusting lifestyle at first. For hypertension and high blood pressure, 
treatment and care other than drug administration have been 
conventionally called “non-drug therapy”. In addition to patients 
who have been already diagnosed and suffering from hypertension, 
there are many subjects in preclinical stage of hypertensive tendency. 
Such people must be considered for healthier life from the viewpoint 
of first prevention of hypertension at the preclinical stage [21].
There was a guideline for hypertension presented in 2017. It was 
High Blood Pressure Clinical Practice Guideline as A Report of the 
American College of Cardiology/American Heart Association Task 
Force on Clinical Practice Guidelines. As for nonpharmacological 
Interventions, it recommended 6 possible preventive or treatable 
factors. They are weight loss [22], a heart-healthy diet such as the 
DASH (Dietary Approaches to Stop Hypertension) diet [23], sodium 
reduction [24], potassium supplementation [21], increased physical 
activity and reduction in alcohol consumption [25]. 
There is a report on the withdrawal of antihypertensive medicine 
at a Japanese clinic which is specific to hypertension [26]. There 
are thousands of cases of hypertension annually, among which the 
percentage of antihypertensive drugs that could be withdrawn was 
4.6%-6.1% over the last few years. Among them, 50 cases in which 
antihypertensive drugs were discontinued (25 cases in both males 
and females) were examined. As a result, the family history of 
hypertension was 33 cases (66%) in women, smoking in men was 76%, 
alcohol consumption in men was 60%, besides 42% for dyslipidemia 
and 12% for type 2 diabetes. Usually, it can be judged that 12% seems 
to be low as compared with the prevalence of diabetes in patients with 
hypertension.
One reason for this would be that there are microangiopathy and 
macroangiopathy due to the complication of diabetes. Consequently, 
it may be related to the existence of impaired function of blood 
vessel. In other words, it is presumed that improvement of blood 
pressure control is not easy due to vascular disorders developed by 
the influence of diabetes.
 Furthermore, examining the six cases (12%) out of 50 cases, it was 
characterized that the body weight was reduced by 2.8 kg on average 
by improving the meal and lifestyle habits. Therefore, it seems that 
there is a relation with the significant improvement of the condition 
of diabetes. 
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Up to this point, recent trend and research results of hypertension 
was described. Subsequently, development of guideline for diabetes 
will be shown. The main purpose and target of diabetes therapy is the 
prevention of complications [27]. For years, the endpoint of many 
clinical trials is to lower blood glucose levels, but intensive treatments 
aimed at lowering the HbA1c to less than 6.5% are often accompanied 
by hypoglycemia as a side effect. At the same time, intensive regimens 
have not shown a reduction of cardiovascular complications in the 
long-term [28-32]. For example, the action to control cardiovascular 
risk in diabetes (ACCORD) trial was prematurely discontinued, 
following the observation of an increase in overall mortality, 
cardiovascular-related deaths, and severe hypoglycemic events [28].
Regarding the process of diabetes guidelines, comments have 
been made from different positions in each country and each 
organization. In the United States, there were some guidelines and 
statements on diabetes guidelines, including the American Diabetes 
Association (ADA), the American Society of Clinical Endocrinology, 
and the American Endocrine Society (AACE/ACE). However, there 
was a difference in the contents, and confusion was actually seen in 
the clinical setting.
Therefore, the Clinical Guidelines Committee of the American 
College of Physicians (ACP) independently evaluated several 
guidelines, and released a statement on ACP’s own HbA1c 
management goal. ACP is an authoritative conference and highly 
reliable for years. Unlike ADA and AACE / ACE guidelines, the 
statement of ACP is extremely shocking, with a management goal of 
type 2 diabetes patients under medication of 7% to 8% HbA1c [33]. 
Prior to presentation, ACP examined the guidelines for 
the existing HbA1c management objectives of six academic 
organizations. They included AACE / ACE, ADA, the Institute for 
Clinical Systems Improvement (ICSC), the UK National Clinical 
Evaluation laboratory (NICE), Scottish University guideline network 
(SIGN), US Department of Veterans Affairs and US Department of 
Defense guidelines (VA / DoD) [34-39].
Furthermore, these studies were based on 5 well-known previous 
mega studies, including 1) UKPDS 33, 34, 2) UKPDS 80, 3) ACCORD 
4) ADVANCE, 5) VADT associated with lots of reliable data 
accumulation.
As described above, there have been some transition in guidelines 
for hypertension and diabetes. Further development will be expected 
by accumulation of medical treatment and clinical research in the 
future.
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